Physician profile
Robert A Gordon
NPI 1417974973
$19,879.48
in general payments reported to CMS, 2019-2025
24 companies · $6,087 in 2025
The $6,087 reported for 2025 was more than what 93% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,624 · 2020: $368 · 2021: $594 · 2022: $576 · 2023: $6,596 · 2024: $1,033 · 2025: $6,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Food and Beverage: $3,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,362.50 |
| Food and Beverage | $3,353.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $5,146.19 | 2020-2025 | Camzyos, Eliquis |
| Cvrx, INC. | $3,492.31 | 2023-2025 | Barostim Neo System |
| Abiomed | $3,258.18 | 2019-2024 | Impella |
| Novartis Pharmaceuticals Corporation | $3,010.77 | 2023-2025 | Entresto |
| Akcea Therapeutics, INC. | $2,191.04 | 2019 | |
| Abbott Laboratories | $839.03 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Id Now Instrument |
| Astrazeneca Pharmaceuticals LP | $343.51 | 2021-2023 | Farxiga |
| Novo Nordisk INC | $309.49 | 2020-2025 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $207.16 | 2021-2024 | |
| Medtronic, INC. | $205.10 | 2021-2025 | Vitalflow Console |
| Alnylam Pharmaceuticals INC. | $140.55 | 2022-2025 | Onpattro |
| Merck Sharp & Dohme LLC | $126.53 | 2023-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $103.89 | 2023-2025 | Lifevest |
| Edwards Lifesciences Corporation | $83.68 | 2025 | Sapien 3 Ultra Resilia |
| Pfizer INC. | $73.54 | 2024-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $71.37 | 2023 | Inpefa |
| Bridgebio Pharma, INC. | $66.95 | 2025 | Attruby |
| Lilly USA, LLC | $40.70 | 2024-2025 | Mounjaro |
| Scpharmaceuticals INC. | $37.95 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.12 | 2021 | |
| Boston Scientific Corporation | $28.48 | 2025 | Watchman Flx |
| Kiniksa Pharmaceuticals International, Plc | $26.47 | 2024 | Arcalyst |
| Corcept Therapeutics | $25.89 | 2025 | Korlym |
| Angiodynamics, INC. | $17.58 | 2023 | Alphavac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.